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1. Introduction
Selective internal radiation therapy (SIRT) can be sim-
ulated by means of scintigraphy performed after intra-
arterial hepatic injection of technetium-99m-labelled
macro-aggregated-albumin (99mTc-MAA). SIRT simulation
is essential to evaluate the potential non-targeted
distribution of yttrium-90 (90Y) resin microspheres as
well as to inform the predicted dose distribution in the
tumour and liver parenchyma, and treatment planning
(assessment of the most appropriate catheter position
for SIRT administration). Treatment veriﬁcation using
Bremsstrahlung SPECT-CT or 90Y-PET-CT after SIRT
should always be performed in order to conﬁrm the
quality of simulation for each patient.
2. Predicting extrahepatic distribution
Provided that both the tracer and microspheres are in-
jected under the same conditions, 99mTc-MAA SPECT-CT
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provides an accurate picture of the microspheres
disposition within the liver as well as any undesirable
extrahepatic spread to the lungs, gastro-duodenal tract,
abdominal wall and gall bladder. 1,2 A number of clinical
groups have shown that 99mTc-MAA SPECT integrated
with low-dose CT provides a more accurate picture
of the biodistribution of microspheres beyond liver
compared with 99mTc-MAA SPECT alone. 3,4 The detection
of gastrointestinal shunting using 99mTc-MAA SPECT-CT,
for example, is four times more sensitive and conse-
quently associated with lower rates of complications
than SPECT-imaging alone. 3 Perchlorate should always
be administered just before start of the simulation
catherisation session to block the free 99mTc uptake in the
stomach wall which might mask or mimic extrahepatic
MAA particle deposition.
3. Catheter positioning and super-selective
irradiation
Reported cases of discordances between simulation MAA
SPECT and Bremsstrahlung SPECT following SIRT with
90Y resin microspheres have raised questions on the use
of MAA as a tracer for SIRT simulation. 5,6 MAA particles
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Fig. 1 – FDG PET-CT image showing recurrent colorectal liver
metastasis with increased glucose metabolism posterior in
the right lobe. Spatial registration of PET with early arterial
phase angio-CT (3D-rendering images shown on the right
side of the image) allows the identiﬁcation of the feeding
hepatic artery of the tumour before starting the simulation
arteriography. This patient will be treated with high-dose
supraselective SIRT.
are not exactly identical to resin microspheres in
shape and size (10−90 mm versus 30mm). In addition,
there are also differences in ﬂow redistribution: active
treatment is associated with progressive embolisation
while MAA administration has no signiﬁcant embolic
effect on the hepatic arterial circulation. In practice
however, recent data (to be published shortly) indicate
that the disparity in the intrahepatic distribution of MAA
and 90Y microspheres is mainly due to (often small)
differences in catheter positioning during the simulation
and active treatment. Therefore, before simulation is
started, the treatment ﬁeld of view and catheter
position should be carefully predeﬁned. This requires
inter-disciplinary collaboration between the oncologist/
oncosurgeon, the nuclear medicine physician and the
interventional radiologist, before simulation. Deﬁning
the cathether position requires knowledge of the disease
activity and localisation (often requiring PET-CT imaging
or functional MRI as previous local or systemic liver
treatments can make this analysis inaccurate using
structural imaging tools). Secondly, it should be decided
whether a whole-liver or supraselective approach is
indicated. This decision should be informed by the
detailed anatomy of the arterial supply. This can be
obtained by means of spatial registration of PET/MRI
images with early arterial phase angio-CT (Fig. 1), which
can depict the tumour arterial vasculature almost as
precisely as digital subtraction angiography. 7
These pre-treatment procedures are essential in
ensuring that the radiation ﬁeld is adapted to the
regions of active disease. With more targeted delivery of
microspheres, the dose in the lesion can be increased
without a signiﬁcant increase in toxicity. By limiting the
administration of 90Y microspheres to predeﬁned areas of
the liver, it is anticipated that SIRT will become a major
tool in the multimodality treatment of patients with
borderline or non-resectable, liver-only metastases.
4. Predictive dosimetry
Predictive dosimetry is based on the assumption that
the MAA distribution during simulation is predictive
of the distribution of 90Y microspheres during SIRT.
In recent years, Kennedy and colleagues from Wake
Radiology Oncology, Cary, NC, USA have developed an
automated technique using 3-D Monte-Carlo dose kernel
simulations to generate 3-D dose maps for the lesion and
liver parenchyma based on 99mTc-MAA SPECT. 8,9 Through
image registration between MAA SPECT-CT and PET or
MRI on which active tumour lesions are delineated, a
lesion-by-lesion prediction of absorbed radiation dose
per injected 90Y-activity can be calculated. 10 The same
can be done for the normal liver parenchyma which
leads to an individualisation of dose-limiting toxicity. It
is generally believed that the patient-speciﬁc dosimetry
will gradually replace the present BSA-based dosing
algorithm.
5. Is MAA-based dosimetry related to response?
We have observed a good correlation between the
simulated absorbed dose based on MAA on SPECT-CT
and the metabolic response (change in total lesion
glycolysis) to 90Y on FDG-PET at 6 weeks in metastatic
colorectal cancer. 10 The uptake ratio of MAA in the
tumour compared to the normal liver parenchyma
should be higher than 1 in order to obtain a signiﬁcant
metabolic response. Therefore, the simple rule for SIRT
eligibility should be that the liver tumours should appear
as hot spots on the MAA SPECT-CT. It was also shown
that the MAA-uptake in colorectal liver metastases is
highly variable inter- and intra-individually, resulting in
variable lesion response. Therefore, the MAA SPECT-CT
simulation data are essential in informing the decision
of the tumour board on how and when SIRT should
be optimally implemented within the multimodality
treatment of a particular patient.
Our ﬁndings have been conﬁrmed by a recent study,
which has shown that dosimetry based on 99mTc-MAA
SPECT-CT not only accurately predicts tumour response,
but also overall survival in patient with hepatocellular
carcinoma. 11 This paper is very signiﬁcant because it
is the ﬁrst to show a correlation between predictive
dosimetry based on simulation data and treatment out-
come.
6. Conclusion
In conclusion, the ﬁndings from the 99mTc-MAA SPECT-CT
are an integral part of the treatment planning by
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the multidisciplinary team. Treatment simulation using
99mTc-MAA SPECT-CT has not only improved the safety
of SIRT but can now be used in predictive dosimetry and
may provide some insights into the response to SIRT.
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